No Data
No Data
Medytox (688373.SH): The proposed investment amount in MicuRx Pharmaceuticals, Inc. is adjusted from $80 million to $60 million.
On October 9th, Geelong announced that Mengke Pharmaceuticals (688373.SH) plans to adjust the investment amount in MicuRx Pharmaceuticals, Inc. from $80 million to $60 million, with the contribution method still being cash investment. The company will, based on the funding situation, authorize management to implement the capital increase scheme in batches with its own or self-raised funds after completing the corresponding approval procedures.
Shanghai MicuRx Pharmaceutical Co., Ltd. (SHSE:688373) Surges 16%; Private Companies Who Own 30% Shares Profited Along With Institutions
Mengke Pharmaceutical: Achieved revenue of 60.74 million yuan in the first half of 2024, a year-on-year increase of 44%.
In the first half of 2024, the revenue reached 60.7382 million yuan, a year-on-year increase of 44.24%. Research and development investment reached 166.1674 million yuan, a year-on-year increase of 72.91%; R&D investment accounted for 273.58% of revenue, an increase of 45.37 percentage points from the same period last year. Shanghai, September 2, 2024 / PRNewswire/ -- On August 29, 2024, Shanghai Mengke Pharmaceutical Co., Ltd. ("Mengke Pharmaceutical", 688373.SH) disclosed its semi-annual report for 2024. During the reporting period, the company achieved revenue of 60.7382 million yuan, an increase compared to the same period last year.
Shanghai Mengke Pharmaceutical Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Shanghai Mengke Pharmaceutical Co., Ltd.
Meinuo Pharmaceutical (688373.SH) released its first half financial performance, with a net loss of 0.201 billion yuan.
Mengke Pharmaceutical (688373.SH) released its semi-annual report for 2024, during which period the company achieved revenue...
No Data
No Data